Abcam (LON:ABC)‘s stock had its “hold” rating reaffirmed by analysts at Peel Hunt in a research report issued on Tuesday.
Several other research analysts have also commented on ABC. Berenberg Bank lowered shares of Abcam to a “hold” rating and decreased their price target for the company from GBX 1,240 ($16.51) to GBX 1,230 ($16.38) in a report on Monday, March 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 946 ($12.59) price target on shares of Abcam in a report on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Abcam has an average rating of “Hold” and a consensus price target of GBX 1,135.25 ($15.11).
Shares of Abcam opened at GBX 1,374 ($18.29) on Tuesday, MarketBeat.com reports. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,290 ($17.17).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents.
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.